Background and Purpose-To investigate the prognostic value of cerebral microbleeds (CMB) regarding overall, cardiovascular-related, and stroke-related mortality and to investigate possible differences based on a cerebral amyloid angiopathy-type and nonlobar distribution of microbleeds. Methods-We included 435 subjects who were participants from the nested MRI substudy of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Cox proportional hazard models were applied to estimate the risk of overall, cardiovascular-related, and stroke-related death associated with microbleeds in general and microbleeds with a lobar distribution suggestive of the presence of cerebral amyloid angiopathy. The corresponding Kaplan-Meier survival curves were calculated. Results-Subjects with Ͼ1 CMB had a 6-fold risk of stroke-related death compared to subjects without CMB (hazard ratio, 5.97; 95% CI, 1.60 -22.26; Pϭ0.01). The diagnosis of nonlobar microbleeds was associated with Ͼ2-fold risk of cardiovascular death compared to subjects without microbleeds (hazard ratio, 2.67; 95% CI, 1.23-5.81; Pϭ0.01). Subjects with probable cerebral amyloid angiopathy-type microbleeds had Ͼ7-fold risk of stroke-related death compared to subjects without CMB (hazard ratio, 7.20; 95% CI, 1.44 -36.10; Pϭ0.02). Conclusions-This is the first study investigating the association between microbleeds and risk of overall, cardiovascular-related, and stroke-related mortality in an elderly population. Our findings indicate that the diagnosis of microbleeds is potentially of clinical relevance. Larger studies are needed to expand our observations and to address potential clinical implications and cost-benefits of such a policy. (Stroke. 2011;42:638-644.)
C erebral microbleeds (CMB) are focal hemosiderin deposits that result from minimal blood leakage from damaged small vessels 1 and can be regarded as markers of pathological vascular changes. 2 Concerning histopathology, the 2 most common types of underlying small vessel damage are hypertensive vasculopathy and cerebral amyloid angiopathy (CAA). 1, 3, 4 The location and distribution of CMB depend on the type of underlying vasculopathy; whereas hypertensive CMB preferentially occur in deep brain regions such as the basal ganglia, thalamus, or brain stem, CAA-type CMB are mainly located in the cerebral lobes but never in deep brain regions. 2, [5] [6] [7] CMB are commonly seen in patients with ischemic stroke, 8 intracerebral hemorrhage, 1 Alzheimer's disease, 9 traumatic brain injury-associated diffuse axonal injury, 10 and also in healthy elderly individuals. 11 The prevalence of CMB in the general population increases from Ϸ20% in subjects aged 60 to 69 years to Ϸ40% in subjects aged 80 years and older. 5 Presence of CMB was the strongest predictor of overall mortality among a range of MRI markers of vascular damage in a memory clinic population. 12 It remains to be elucidated whether CMB are predictive of mortality in the general population. Furthermore, it is not known to what extent CMB are specifically associated with cardiovascular mortality or noncardiovascular disease.
In the present study, we investigated the prognostic value of CMB regarding overall, cardiovascular-related, and stroke-related mortality in a population enriched for or at high risk for cardiovascular disease. Moreover, we investigated possible differences in prognostic value based on a CAA-type and nonlobar distribution of CMB.
Subjects and Methods

Study Participants
All subjects are participants from the nested MRI substudy of the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). 13 Inclusion criteria for the PROSPER were men or women aged 70 to 82 years with a total cholesterol of 4.0 to 9.0 mmol/L and a history of either ischemic or hemorrhagic stroke, transient ischemic attack, myocardial infarction, arterial surgery, or amputation for vascular disease, or 1 of the following risk factors for vascular disease: current smoker, hypertension diagnosed, diabetes mellitus, or fasting blood glucose Ͼ7 mmol/L. Of the included subjects, 43% had symptomatic vascular disease. These subjects experienced symptoms Ͼ6 months before entering the study. Exclusion criteria have been described in detail elsewhere. 14 There were no specific inclusion criteria for the MRI substudy. All consenting subjects (646 of the 1100 eligible Dutch participants) were enrolled in the Netherlands from May 2, 1998. CMB were scored on MRI scans obtained at the end of the study. Ninety-two subjects did not undergo an MRI scan because of the following reasons: 44 subjects were ill or had contraindications for MRI, 40 subjects had died, 6 subjects had withdrawn informed consent, and 2 could not undergo a scan because of technical problems. 15 T2*-weighted scans for the detection of CMB were available for 435 subjects. Baseline characteristics of these 435 subjects and the remaining 665 Dutch PROSPER participants were similar, except for the proportion of smokers, which was significantly higher among the 665 Dutch participants (26.8% vs 20.5%; Pϭ0.02). Mortality of study participants was continuously followed-up after the official end of the study until December 31, 2009 . The individual causes of death were obtained through the Central Bureau of Statistics of the Netherlands. All end points were adjudicated by the independent clinical events committee of PROSPER. The protocols meet the criteria of the Declaration of Helsinki and were approved by the Medical Ethics Committees of each participating institution. Written informed consent was obtained from all participating patients.
MRI Scanning
All imaging was performed on an MR system operating at field strength of 1.5 T (Philips Medical Systems). Dual fast-spin echo (repetition timeϭ3000 ms; echo timesϭ27/120 ms; flip angleϭ90°; slice thicknessϭ3 mm; 48 slices; no interslice gap; field of viewϭ220ϫ220 mm; matrixϭ256ϫ204), fluid-attenuated inversion recovery (FLAIR) (repetition timeϭ8000 ms; echo timeϭ100 ms; inversion delayϭ2000 ms; flip angleϭ90°; slice thicknessϭ3 mm; 48 slices; no interslice gap; field of viewϭ220ϫ176 mm; matrixϭ256ϫ153), and T2*-weighted images (multislice gradient echo sequence; repetition timeϭ2593 ms; echo timeϭ48 ms; flip angleϭ60°; slice thicknessϭ6 mm; 22 slices; interslice gapϭ6 mm; whole brain coverage; field of viewϭ220ϫ198 mm; matrixϭ256ϫ176) were obtained from all subjects.
MRI Analysis: Microbleeds
All MRI scans were read in consensus by 2 experienced raters (A.C.G.M.v.E. and M.A.v.B.), who were blinded to the clinical history. CMB were defined as focal areas of signal loss on T2-weighted images that increased in size on the T2*-weighted gradient-echo planar images ("blooming effect"). 2 In this way, CMB were differentiated from areas of signal loss based on vascular flow void. Areas of symmetrical hypointensity in the basal ganglia likely to represent calcification or nonhemorrhagic iron deposits were disregarded. For each subject, number and location (corticosubcortical junction, deep white matter, basal ganglia, and infratentorial) of CMB were recorded. All study participants were assigned to one of the following groups according to the number of CMB: no microbleeds, 1 microbleed, Ͼ1 microbleed.
Subsequently, we applied the Boston criteria for CAA to all subjects. The Boston criteria are designed to estimate the likelihood of the presence of CAA during life by means of location and number of intracerebral hemorrhages. We categorized subjects as having no microbleeds, possible CAA (MRI demonstrating a single lobar, cortical, or corticosubcortical hemorrhage without any other cause of hemorrhage), probable CAA (MRI demonstrating multiple lobar, cortical, or corticosubcortical hemorrhages without any other cause of hemorrhage), or microbleeds not qualifying for CAA (nonlobar microbleeds). 7, 16, 17 MRI Analysis: White Matter Lesions, Atrophy, and Cerebral Infarction Segmentation of white matter lesions (WML), intracranial volume, and brain parenchyma volume was performed automatically using Software for Neuro-Image Processing in Experimental Research, 18 a program developed in-house for image processing. This segmentation was performed on the T2-weighted and FLAIR images. WML connected to the lateral ventricles were labeled as periventricular WML, and WML not connected to the lateral ventricles were labeled as deep WML. 15 The volumes of periventricular WML and deep WML were calculated automatically by Software for Neuro-Image Processing in Experimental Research. All measurements were performed blinded to subject identity, age, and sex. A measure reflecting whole brain atrophy and hippocampal atrophy was calculated using the following equa- Table 1 tions: atrophy (%)ϭ[(intracranial volumeϪparenchymal volume)/ intracranial volume]ϫ 100% and hippocampal atrophy (%)ϭ(hippocampal volume/intracranial volume)ϫ100%, respectively. 19, 20 Cortical infarcts were defined as cortical defects surrounded by a hyperintense zone on T2-weighted scans. Lacunar infarcts were defined as parenchymal defects, not extending into the cortex, surrounded by a hyperintense zone (Ն3 mm, Ͻ15 mm in diameter) on a T2-weighted scan. Dilated perivascular spaces were distinguished from infarcts on the basis of their location, form, and the absence of a hyperintense zone around the parenchymal defect.
Statistical Analysis
For statistical analysis, SPSS software for windows (version 17.0.1; SPSS) was used. Kaplan-Meier survival curves for overall, cardiovascular-related, and stroke-related mortality were calculated for no, 1, and Ͼ1 microbleed, possible and probable CAA-type CMB, and nonlobar microbleeds. We applied Cox proportional hazard models to estimate the risk of overall, cardiovascular-related, and stroke-related death associated with these microbleed categories in 2 different ways: adjusting for age, sex, and use of statins (model 1; nϭ435 for overall mortality, nϭ434 for cardiovascular-related and stroke-related mortality; the cause of death of 1 subject was missing) and additionally adjusting for cardiovascular risk factors (alcohol use, smoking, body mass index, high-density lipoprotein cholesterol, systolic and diastolic blood pressure, and history of hypertension/diabetes mellitus/ischemic or hemorrhagic stroke/transient ischemic attack; model 2; nϭ418 for overall mortality, nϭ417 for cardiovascular-related and stroke-related mortality; the cause of death of 1 subject was missing).
Results
Baseline characteristics of the study population are shown in Table 1 . In total, 435 participants with a mean age of 75.0 years and a female fraction of 43.6% were included in the present study. The mean follow-up duration for determining mortality was 7.0 (Ϯ2.1) years. In this period, 153 subjects (34.9%) died, of whom 57 (37.3%) died of cardiovascular causes: 14 had an ischemic or hemorrhagic stroke, 43 subjects died of cardiovascular causes not affecting the brain, and the cause of death of 1 subject was missing. The individual amount of CMB was not significantly different between subjects treated with statins and subjects treated with placebo (data not shown). History of hypertension was significantly associated with the diagnosis of CMB independent of the other mentioned cardiovascular risk factors (Pϭ0.005; data not shown).
First, we investigated the risk of overall, cardiovascular-related, and stroke-related death associated with the diagnosis of no, 1, or Ͼ1 microbleed. Subjects with Ͼ1 microbleed diagnosed had an increased risk of overall death compared to subjects without CMB after adjustment for age, sex, use of statins, and cardiovascular risk factors not reaching statistical significance (hazard ratio [HR], 1.41; 95% CI, 0.87-2.27; Pϭ0.16). The risk of cardiovascular death for these subjects was broadly similar (HR, 1.78; 95% CI, 0.86 -3.70; Pϭ0.12; Table 2 ). Strikingly, subjects with Ͼ1 microbleed diagnosed had Ϸ6-fold risk of stroke-related death compared to subjects without microbleeds after adjustment for age, sex, use of statins, and cardiovascular risk factors (HR, 5.97; 95% CI, 1.60 -22.26; Pϭ0.01). Figure 1 shows the corresponding Kaplan-Meier survival curves for overall ( Figure 1A) , cardiovascular ( Figure 1B) , and stroke-related mortality ( Figure 1C) .
Subjects with nonlobar microbleeds diagnosed had Ͼ2-fold risk of cardiovascular death compared to subjects without CMB after adjustment for age, sex, use of statins, and cardiovascular risk factors (HR, 2.67; 95% CI, 1.23-5.81; Pϭ0.01; Table 3 ). This association remained unchanged after additional adjustment for other cerebral changes on MRI (cerebral and hippocampal atrophy, WML, cortical and lacunar infarctions; HR, 3.03; 95% CI, 1.34 -6.85; Pϭ0.01). The corresponding Kaplan-Meier survival curves are shown in Figure 2A . Approximately 65% of these subjects had CMB located in the basal ganglia diagnosed, 52% had cerebellar CMB diagnosed, 32% had lobar CMB diagnosed, 13% had CMB located in the brain stem diagnosed, and 45% had CMB in at least 2 Subjects with probable CAA-type microbleeds diagnosed were exposed to Ͼ7-fold risk of stroke-related death compared to subjects without CMB after adjustment for age, sex, use of statins, and cardiovascular risk factors 
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(HR, 7.20; 95% CI, 1.44 -36.10; Pϭ0.02). The corresponding Kaplan-Meier survival curves are shown in Figure 2B . Neither probable CAA-type CMB nor possible CAA-type CMB were associated with an increased risk of overall or cardiovascular death. Combining probable and possible CAA patients in 1 group did not change these results.
Discussion
The most important findings of this population-based study in elderly individuals are that nonlobar microbleeds are significantly and independently associated with cardiovascular mortality and that probable CAA-type microbleeds are significantly associated with stroke-related mortality. Nonlobar CMB seem to represent a sensitive marker of increased cardiovascular risk beyond traditional cardiovascular risk factors. Presence of nonlobar CMB was significantly associated with an increased risk of cardiovascular-related but not stroke-related death, independent of cardiovascular risk factors and other cerebral changes on MRI, such as cortical and hippocampal atrophy, WML, and cortical and lacunar infarctions, which have been partly shown to be associated with mortality as well. 12, [21] [22] [23] CMB have been shown to be associated with primary and recurrent intracerebral hemorrhage, 24 -31 and especially nonlobar microbleeds are strongly associated with hypertension and elevated systolic blood pressure, the traditional risk factors for hemorrhagic and ischemic stroke. 5, 32, 33 Against this background our results are striking, indicating that nonlobar CMB can be regarded as an additional marker of an unfavorable cardiovascular risk profile beyond traditional cardiovascular risk factors, such as hypertension or smoking, and other imaging markers of hypertension, such as left ventricular hypertrophy, which has been established as a predictor of excess cardiovascular mortality. 34 Further studies will be needed to compare the predictive strength of nonlobar CMB against alreadyestablished imaging markers of cardiovascular mortality such as left ventricular hypertrophy. However, the value of this finding is limited by the small proportion of subjects with nonlobar CMB diagnosed who died from cardiovascular disease or stroke during follow-up.
CAA-type CMB seem to be markers of an increased risk of stroke-related death, independent of cardiovascular risk factors. However, the number of subjects who died from stroke was small. Furthermore, we could not differentiate between hemorrhagic and ischemic stroke as primary outcome and therefore are not able to further comment about possible associations between CAA-type microbleeds and hemorrhagic or ischemic stroke. Further studies are needed to assess the validity and possible underlying mechanisms of the association between probable CAAtype microbleeds and stroke-related mortality.
The association of CMB with mortality depends on the number of CMB diagnosed in subjects. We could show that subjects with 1 microbleed in general or possible CAAtype microbleeds diagnosed had no increased risk of mortality, whereas subjects with Ͼ1 microbleed in general or probable CAA-type microbleeds diagnosed were exposed to an increased risk of death. Within the group of subjects with nonlobar microbleeds, presence of Ն1 CMB was associated with an increased risk of mortality. Until now, there was only 1 study investigating the association between CMB and overall mortality in a memory clinic population. 12 In this study, the diagnosis of Ն3 microbleeds was associated with an increased risk of overall death. However, because the conspicuity and therefore the accuracy of detection of CMB are strongly affected by the used MRI technique, available MRI field strength, and image post-processing, 2 it remains difficult to compare these studies.
A strength of our study is the population-based setting in elderly individuals with or at high risk for vascular disease developing. Although our results might not be generalizable to the general elderly population, we were able to assess the predictive value of CMB in a population in which CMB are most likely to be clinically relevant. Furthermore, the large sample size and high prevalence of CMB in this specific population allowed us to assess the association between CMB and different outcome parameters, such as overall, cardiovascular-related, and strokerelated death, and to analyze these associations for different classifications of CMB and CMB in separate anatomic regions. However, there are also several limitations of this study. First, the adjudication of the primary outcome from the national registry instead of formal follow-up limited the possibility to reliably assess the association between CMB and different outcome parameters. One example is the missing differentiation between hemorrhagic and ischemic strokes. Second, the number of events during follow-up was relatively small, so the association between 1 microbleed in general or possible CAA and strokerelated mortality could not be assessed. Because we did not include other established neuroimaging markers of, for instance, cardiovascular mortality, such as left ventricular hypertrophy, in our study design we were not able to compare the predictive strength of CMB against these markers. Further studies will be needed to address this issue. Furthermore, our results are limited to a small group of elderly individuals enriched for or at high risk for cardiovascular disease and therefore were neither generalizable to the whole study cohort nor to the general elderly population.
Conclusion
In conclusion, this is the first study to our knowledge investigating the association between CMB and risk of overall, cardiovascular-related, and stroke-related mortality in an elderly population enriched for or at high risk for cardiovascular disease. Our findings indicate that the diagnosis of CMB is potentially of clinical relevance. Elderly people with CMB and additional cardiovascular risk factors could benefit from special cardiovascular monitoring to prevent death from cardiovascular complications. Larger studies are needed to expand our observations and to address potential clinical implications and cost-benefits of such a policy.
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